Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    21849486 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Condition: Leukemia
Interventions: Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide
2 Recruiting Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Conditions: Leukemia;   Acute Lymphoblastic Leukemia
Intervention: Biological: gene-modified T cells targeted

Indicates status has not been verified in more than two years